You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Trametinib

Showing 51 - 75 of 253
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Amyotrophic Lateral Sclerosis Trial in Busan, Seoul (Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg))

Recruiting
  • Amyotrophic Lateral Sclerosis
  • Trametinib (0.5 mg)
  • +2 more
  • Busan, Korea, Republic of
  • +4 more
Feb 13, 2022

Patients With Completely Resected High-risk Stage III Melanoma.

Recruiting
  • Melanoma
  • Bursa, Gorukle, Turkey
  • +9 more
Feb 28, 2022

Grade 1 Glioma, Mixed Glio-neuronal Tumors, Pleomorphic Xanthoastrocytoma Trial in Strasbourg (Trametinib, Vinblastine)

Recruiting
  • Grade 1 Glioma
  • +2 more
  • Strasbourg, France
    CHU Strasbourg - France
Jul 7, 2022

Melanoma Trial in Boston (Trametinib, Dabrafenib, INCB039110)

Active, not recruiting
  • Melanoma
  • Trametinib
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Nov 1, 2021

Rosacea, Erythematotelangiectatic Trial in Albany (Trametinib)

Recruiting
  • Rosacea, Erythematotelangiectatic
  • Trametinib
  • Albany, New York
    Samuel S. Stratton VA Medical Center
Nov 9, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 10, 2022

Anaplastic Thyroid Cancer Trial in United States (Trametinib, Paclitaxel)

Active, not recruiting
  • Anaplastic Thyroid Cancer
  • Basking Ridge, New Jersey
  • +6 more
Mar 10, 2022

Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))

Completed
  • Metastatic Melanoma
  • Palliative radiotherapy
  • Dabrafenib and trametinib (combination)
  • Darlinghurst, New South Wales, Australia
  • +2 more
Apr 6, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in United States (Dabrafenib Mesylate, Tazemetostat

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Melanoma
  • Dabrafenib Mesylate
  • +2 more
  • Atlanta, Georgia
  • +6 more
Nov 30, 2022

Melanoma Trial in Louisville (Dabrafenib, Trametinib, Metformin)

Recruiting
  • Melanoma
  • Louisville, Kentucky
  • +1 more
Oct 22, 2021

Advanced BRAF Mutant Melanoma Trial in United States (Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally

Completed
  • Advanced BRAF Mutant Melanoma
  • Trametinib 2 mg daily
  • +2 more
  • Chicago, Illinois
  • +3 more
Jan 18, 2022

Anaplastic Thyroid Cancer Trial in Leiden (dabrafenib/trametinib)

Recruiting
  • Anaplastic Thyroid Cancer
  • Leiden, Zuid-Holland, Netherlands
    Ellen Kapiteijn
Oct 5, 2023

Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial

Active, not recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +4 more
  • Dabrafenib Mesylate
  • +3 more
  • Philadelphia, Pennsylvania
    Perelman Center for Advanced Medicine
Dec 29, 2021

Metastatic Thyroid Cancer Trial in Essen (Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2)

Recruiting
  • Metastatic Thyroid Cancer
  • Trametinib 2 MG [Mekinist]
  • Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]
  • Essen, Northrhine-Westphalia, Germany
    Manuel M. Weber
May 17, 2022

Stage IV Melanoma, Stage III Melanoma Trial in Jette (Trametinib, Dabrafenib)

Recruiting
  • Stage IV Melanoma
  • Stage III Melanoma
  • Jette, Brussels, Belgium
    Universitair Ziekenhuis Brussel
Sep 29, 2021

Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer Trial in United States (trametinib, fluorouracil,

Active, not recruiting
  • Recurrent Rectal Cancer
  • +6 more
  • trametinib
  • +2 more
  • Saint Louis, Missouri
  • +3 more
Feb 15, 2022

Cancer, Melanoma Trial in Worldwide (Dabrafenib, Trametinib)

Completed
Has Results
  • Cancer
  • Melanoma
  • Guangzhou, Guangdong, China
  • +12 more
Jan 4, 2022

Advanced Malignancies Trial in Hangzhou (HRS2300, HRS2300? SHR-1316, HRS2300?SHR-1701)

Recruiting
  • Advanced Malignancies
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 31, 2021

BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma

Active, not recruiting
  • Melanoma
  • Dabrafenib and Trametinib
  • Buxtehude, Niedersachsen, Germany
  • +35 more
Aug 25, 2022

Recurrent World Health Organization (WHO) Grade II Glioma Trial in United States (Everolimus, Trametinib)

Recruiting
  • Recurrent World Health Organization (WHO) Grade II Glioma
  • Birmingham, Alabama
  • +11 more
May 6, 2022

metAsTatI? melanOma Treated With dabrafeNib and trAmetinib in

Recruiting
  • Melanoma Stage III
  • +2 more
  • Barnaul, Alatai, Russian Federation
  • +14 more
May 29, 2022

KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma

Active, not recruiting
  • KRAS Gene Mutation
  • +3 more
  • Pembrolizumab
  • Trametinib
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Nov 1, 2021

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

Differentiated Thyroid Cancer Trial in Worldwide (Dabrafenib, Trametinib, Trametinib )

Recruiting
  • Differentiated Thyroid Cancer
  • Caba, Buenos Aires, Argentina
  • +41 more
Nov 25, 2022

Melanoma Trial in Italy (dabrafenib, Trametinib)

Recruiting
  • Melanoma
  • Meldola, Forlì-Cesena, Italy
  • +15 more
Mar 18, 2022